WHEN YOU SEE IT, BE PREPARED

Generalized Pustular Psoriasis (GPP) is a rare and potentially life-threatening skin disease1 distinct from Plaque Psoriasis.2Caused by dysregulation of the IL36- pathway,3GPP flares can affect every aspect of a patient’s life, Effective, fastacting, GPP-specific therapies are needed to control them.4

Volcano bursting through dermatologist’s door

GPP= Generalized Pustular Psoriasis; IL36-=interleukin36-.

REFERENCES

  1. Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11(3):e043666

  2. Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907-919.

  3. Marrakchi S, Puig L. Pathophysiology of Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23:13-19.

  4. Strober B, Kotowsky N, Medeiros R, et al. Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists. Dermatol Ther (Heidelb). 2021;11(2):529-541.

  5. Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109-120.